# Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays

> **NCT04074993** · PHASE2 · UNKNOWN · sponsor: **JI-YOUN HAN** · enrollment: 35 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Brigatinib

## Key facts

- **NCT ID:** NCT04074993
- **Lead sponsor:** JI-YOUN HAN
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-15
- **Primary completion:** 2025-01-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2023-09-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04074993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04074993, "Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04074993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*